Dietary phosphate restriction ameliorates endothelial dysfunction in adenine-induced kidney disease rats

Journal of Clinical Biochemistry and Nutrition

Volumn 51, Issue 1, 2012, Pages 27-32

  Van, Tan Vu ^a   Watari, Eriko ^a   Taketani, Yutaka ^a   Kitamura, Tomoyo ^a   Shiota, Asuka ^a   Tanaka, Terumi ^a   Tanimura, Ayako ^a   Harada, Nagakatsu ^a   Nakaya, Yutaka ^a   Yamamoto, Hironori ^a   Miyamoto, Ken Ichi ^a   Takeda, Eiji ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Akt; Cardiovascular disease; Chronic kidney disease; Endothelial nitric oxide synthase; Hyperphosphatemia

Indexed keywords

ACETYLCHOLINE; ADENINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; PHOSPHATE; PROTEIN KINASE B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DIETARY PHOSPHATE RESTRICTION; DRUG INDUCED DISEASE; ENDOTHELIAL DYSFUNCTION; HYPERPHOSPHATEMIA; KIDNEY DISEASE; KIDNEY FAILURE; MALE; NONHUMAN; RAT; VASCULAR DISEASE; VASCULAR RING; VASODILATATION;

ANIMALIA; RATTUS;

EID: 84863498964     PISSN: 09120009     EISSN: None     Source Type: Journal    
DOI: 10.3164/jcbn.11-96     Document Type: Article

References (30)

1. Foley RN, Collins AJ, Herzog CA, Ishani A, Kalra PA. Serum phosphorus levels associate with coronary atherosclerosis in young adults. J Am Soc Nephrol 2009; 20: 397-404.
2. Kesternbaum B. Phosphate metabolism in the setting of chronic kidney disease: significance and recommendations for treatment. Seminar Dial 2007; 20: 286-294.
3. Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G; Cholesterol and Recurrent Events Trial Investigators. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005; 112: 2627-2633. (Pubitemid 41532599)
4. Dhingra R, Sullivan LM, Fox CS, et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 2007; 167: 879-885. (Pubitemid 46762749)
5. Menon V, Greene T, Pereira AA, et al. Relationship of phosphorus and calcium-phosphorus product with mortality in CKD. Am J Kidney Dis 2005; 46: 455-463. (Pubitemid 41208181)
6. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001; 38: 938-942. (Pubitemid 34258697)
7. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007; 71: 438-441.
8. Kestenbaum BR, Adeney KL, de Boer IH, Ix JH, Shlipak MG, Siscovick DS. Incidence and progression of coronary calcification in chronic kidney disease: the multi-ethnic study of atherosclerosis. Kidney Int 2009; 76: 991-998.
9. Watanabe R, Lemos MM, Manfredi SR, Draibe SA, Canziani ME. Impact of cardiovascular calcification in nondialyzed patients after 24 months of follow-up. Clin J Am Soc Nephrol 2010; 5: 189-194.
10. Onufrak SJ, Bellasi A, Shaw LJ, et al. Phosphorus levels are associated with subclinical atherosclerosis in the general population. Atherosclerosis 2008; 199: 424-431.
11. Shuto E, Taketani Y, Tanaka R, et al. Dietary phosphorus acutely impairs endothelial function. J Am Soc Nephrol 2009; 20: 1504-1512.
12. Kööbi P, Vehmas TI, Jolma P, et al. High-calcium vs high-phosphate intake and small artery tone in advanced experimental renal insufficiency. Nephrol Dial Transplant 2006; 21: 2754-2761. (Pubitemid 44542227)
13. Di Marco GS, Hausberg M, Hillbrand U, et al. Increased inorganic phosphate induces human endothelial cell apoptosis in vitro. Am J Physiol Renal Physiol 2008; 294: F1381-F1387.
14. Mount PF, Kemp BE, Power DA. Regulation of endothelial and myocardial NO synthesis by multi-site eNOS phosphorylation. J Mol Cell Cardiol 2007; 42: 271-279. (Pubitemid 46135596)
15. Yilmaz MI, Saglam M, Caglar K, et al. The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. Am J Kidney Dis 2006; 47: 42-50. (Pubitemid 41828265)
16. Yilmaz MI, Sonmez A, Saglam M, et al. ADMA levels correlates with proteinuria, secondary amyloidosis, and endothelial dysfunction. J Am Soc Nephrol 2008; 19: 388-395. (Pubitemid 351240660)
17. Yu M, Kim YJ, Kang DH. Indoxyl sulfate-induced endothelial dysfunction in patients with chronic kidney disease via an induction of oxidative stress. Clin J Am Soc Nephrol 2011; 6: 30-39.
18. Yimaz MI, Sonmez A, Saglam M, et al. FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease. Kidney Int 2010; 78: 679-685.
19. Caglar K, Yilmaz MI, Saglam M, et al. Serum fetuin-a concentration and endothelial dysfunction in chronic kidney disease. Nephron Clin Pract 2008; 108: c233-c240. (Pubitemid 351588118)
20. Yilmaz MI, Saglam M, Carrero JJ, et al. Serum visfatin concentration and endothelial dysfunction in chronic kidney disease. Nephrol Dial Transplant 2008; 23: 959-965. (Pubitemid 351767576)
21. Schwedhelm E, Böger RH. The role of asymmetric and symmetric dimethylarginines in renal disease. Nat Rev Nephrol 2011; 7: 275-285.
22. Fliser D, Kronenberg F, Kielstein JT, et al. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol 2005; 16: 2456-2461. (Pubitemid 41725064)
23. Terai K, Nara H, Takakura K, et al. Vascular calcification and secondary hyperparathyroidism of severe chronic kidney disease and its relation to serum phosphate and calcium levels. Br J Pharmacol 2009; 156: 1267-1278.
24. Cozzolino M, Dusso AS, Liapis H, et al. The effects of sevelamer hydrochloride and calcium carbonate on kidney calcification in uremic rats. J Am Soc Nephrol 2002; 13: 2299-2308. (Pubitemid 34925240)
25. Fleming I. Molecular mechanims underlying the activation of eNOS. Pflugers Arch 2010; 459: 793-806.
26. Katsumata K, Kusano K, Hirata M, et al. Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats. Kidney Int 2003; 64: 441-450. (Pubitemid 36871915)
27. Neven E, Dams G, Postnov A, et al. Adequate phosphate binding with lanthanum carbonate attenuates arterial calcification in chronic renal failure rats. Nephrol Dial Transplant 2009; 24: 1790-1799.
28. Shuvy M, Abedat S, Beeri R, et al. Uraemic hyperparathyroidism causes a reversible inflammatory process of aortic valve calcification in rats. Cardiovasc Res 2008; 79: 492-499.
29. Zisman AL, Wolf M. Recent advances in the rapidly evolving field of fibroblast growth factor 23 in chronic kidney disease. Curr Opin Nephrol Hypertens 2010; 19: 335-342.
30. Sigrist MK, Chiarelli G, Lim L, Levin A. Early initiation of phosphate lowering dietary therapy in non-dialysis chronic kidney disease: a critical review. J Ren Care 2009; 35 (Suppl 1): 71-78.